Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

Christante, Dara; Pommier, Su Ellen J.; Garreau, Jennifer R.; Müller, Patrick; LaFleur, Brett; Pommier, Rodney F.

doi:10.1016/j.amjsurg.2008.06.023

Cited by 21 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding differs from the findings from previous cohort studies which have consistently shown that HT use is associated with earlier stage and smaller size [2,[28][29][30][31]. Sener et al, for example, reported that HT use was associated with earlier age at diagnosis, biologically more favorable tumors, and higher survival rates [1].…”

Section: Discussioncontrasting

confidence: 56%

“…Whereas some studies suggest that HT use is associated with diagnosis at an earlier stage [1] and hence potentially a better prognosis [2,3], the Women's Health Initiative (WHI) randomized controlled trial has linked HT use with not only an increase in breast cancer risk but also diagnosis at a later stage [4]. Findings from observational studies may have been confounded by greater surveillance among HT users than non-users and potentially differential access to mammographic screening.…”

Section: Introductionmentioning

confidence: 97%

See 1 more Smart Citation

The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics

et al. 2010

View full text Add to dashboard Cite

Exposure to postmenopausal hormone therapy (HT) may affect the stage, histological type, and hormone receptor (HR) status of invasive breast cancer at the time of diagnosis. One thousand six hundred eighty-four women with newly diagnosed first invasive breast cancer were recruited to the "MBF Foundation Health and Wellbeing after Breast Cancer Study." Women using systemic HT estrogen (E) or E combined with progesterone (P) at the time of diagnosis of breast cancer were compared with those not using HT. Breast cancer tumor data were obtained from the Victorian Cancer Registry. Regression analysis was used to determine the associations between HT use or not at the time of diagnosis and tumor histology (ductal vs lobular), stage (I vs II, III, IV), HR status (ER+ or PR+ or both vs ER- or PR-). Of 1,377 women included in the analysis, 226 (16%) were using HT at the time of diagnosis. Of HT users, 20.4% had lobular breast cancer, 50% were stage I, and 85.8% had HR-positive tumors. Of non-users, 13.6% had lobular breast cancer, 48.2% were stage I, and 82.4% had HR-positive tumors. Use of systemic HT was associated with increased odds of having lobular compared with ductal breast cancer (OR = 1.75, 95% CI = 1.14-2.69, p = 0.01). There were no associations between HT use and either breast cancer stage or HR status. Women using systemic HT at the time of diagnosis were more likely to have lobular rather than ductal breast cancer compared with women not on HT.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Introductionmentioning

confidence: 97%

The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics

et al. 2010

View full text Add to dashboard Cite

show abstract

“…7, 10, 11 As the issue of estrogen plus progestin influence on breast cancer mortality has not been addressed in a randomized trial setting, we provide updated information on breast cancer incidence and, for the first time, information on breast cancer mortality related to combined hormone therapy use in the WHI trial.…”

Section: Introductionmentioning

confidence: 99%

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

Chlebowski

Anderson

Gass

et al. 2010

JAMA

504

359

View full text Add to dashboard Cite

“…Multiple studies have investigated the association between risk of breast cancer-related mortality (BCM) and HT with the majority observing a reduced risk of death among women using HT, such as combined estrogen-progestin therapy (EPT) and estrogen-alone therapy (ET) [5, 7, 9, 18, 25, 26, 30, 34]. Previous studies have also reported EPT use and ET use to be associated with many tumor characteristics related to a favorable prognosis [3, 15, 16, 23] with one notable exception [6].…”

Section: Introductionmentioning

confidence: 99%

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

Reding

Doody

McTiernan

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Improved breast cancer survival among hormone replacement therapy users is durable after 5 years of additional follow-up

Cited by 21 publications

References 17 publications

The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics

The Relationship Between Hormone Therapy Use at the Time of Diagnosis of Breast Cancer and Tumor Characteristics

Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

Age-related variation in the relationship between menopausal hormone therapy and the risk of dying from breast cancer

Contact Info

Product

Resources

About